HRAS and urinary bladder cancer: More recently, a combination of methylation status of TWIST, ONECUT2, and OTX1 with mutational analyses of FGFR3, TERT, and HRAS has been reported to detect bladder cancer with a sensitivity of 97% and a specificity of 83% [20, 21].